Specifically, the authors showed that the expression of tumor promoters β-catenin and Wnt2 was inhibited in response to BITC treatment, while the downstream effectors of β-catenin such as cyclinD1 and c-Myc were downregulated. This evidence concerns the gene MYC and neoplasm.